Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Study Details
Study Description
Brief Summary
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, and rituximab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia that is newly diagnosed or that has come back (relapsed). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving venetoclax in combination with dasatinib, prednisone, and rituximab may help treat patients with newly diagnosed or relapsed Philadelphia chromosome positive acute lymphoblastic leukemia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
PRIMARY OBJECTIVES:
-
Determine the maximum tolerated dose (MTD) and/or a recommended phase II dose (RP2D) of venetoclax in combination with dasatinib.
-
Evaluate the safety of venetoclax in combination with dasatinib by assessing the frequency, type, and severity of adverse events.
SECONDARY OBJECTIVES:
-
Assess preliminary response to venetoclax in combination with dasatinib based on minimal residual disease (MRD) negativity.
-
Estimate progression-free and overall survival.
EXPLORATORY OBJECTIVES:
- Evaluate the distribution of BCR-ABL fusion sub-types. II. Assess changes in BCL-family dependence. III. Presence of co-occurring leukemia-specific mutations.
OUTLINE: This is dose-escalation study of venetoclax.
INDUCTION PHASE CYCLE 1: Patients receive prednisone orally (PO) once daily (QD) on days -6 to 21 and rapid taper from days 22-28, dasatinib PO QD days 1-28, venetoclax PO QD days 3-28 or days 3-21, rituximab (for CD20+ patients) intravenously (IV) on days 8 and 15, and methotrexate intrathecally (IT) once during week 1 and once during week 3 in the absence of disease progression or unacceptable toxicity.
INDUCTION PHASE CYCLES 2-3: Patients receive dasatinib PO QD days 1-28, venetoclax PO QD on days 1-28 or 1-21, rituximab (for CD20+ patients) IV on days 1 and 15, and methotrexate IT on days 1 and 15. Treatment repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with clinical benefit may continue to receive treatment for up to 12 months per the discretion of the physician.
After completion of study treatment, patients are followed up at 4 weeks and then every 12 weeks for up to 1 year.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (prednisone, dasatinib, venetoclax, rituximab) INDUCTION PHASE CYCLE 1: Patients receive prednisone PO QD on days -6 to 21 and rapid taper from days 22-28, dasatinib PO QD days 1-28, venetoclax PO QD days 3-28 or days 3-21, rituximab (for CD20+ patients) IV on days 8 and 15, and methotrexate IT once during week 1 and once during week 3 in the absence of disease progression or unacceptable toxicity. INDUCTION PHASE CYCLES 2-3: Patients receive dasatinib PO QD days 1-28, venetoclax PO QD on days 1-28 or 1-21, rituximab (for CD20+ patients) IV on days 1 and 15, and methotrexate IT on days 1 and 15. Treatment repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with clinical benefit may continue to receive treatment for up to 12 months per the discretion of the physician. |
Drug: Dasatinib
Given PO
Other Names:
Drug: Methotrexate
Given IT
Other Names:
Drug: Prednisone
Given PO
Other Names:
Biological: Rituximab
Given IV
Other Names:
Drug: Venetoclax
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of dose-limiting toxicities [At day 32 (after 30 days of combination therapy)]
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications. In order to be declared a dose-limiting toxicity, an adverse experience must be determined related (definitely, probably, or possibly) to study drug. Point estimates and 95% exact confidence intervals will be reported.
- Incidence of adverse events [Up to 90 days after last dose of study drug]
Adverse events will be graded and categorized according to the Common Terminology Criteria for Adverse Events version 5.0. Point estimates and 95% exact confidence intervals will be reported.
Secondary Outcome Measures
- Rate of complete molecular remission (CMR) [Up to completion of cycle 3 (1 cycle = 28 days)]
- Duration of complete molecular response (CMR) [From date of CMR to date of molecular relapse, death or date of last follow-up, assessed up to 12 months after discontinuing study therapy]
The proportion of subjects with CMR as previously defined and its 95% exact confidence interval will be estimated using the efficacy analysis set. Will be estimated using the Kaplan-Meier method along with 95% exact confidence interval.
- Progression-free survival [From first dose of dasatinib to relapse, disease progression, death, date of last follow-up, assessed up to 12 months after discontinuing study therapy]
Will be estimated using the Kaplan-Meier method along with 95% exact confidence interval.
- Overall survival [From first dose of dasatinib to death from any cause, assessed up to 12 months after discontinuing study therapy]
Will be estimated using the Kaplan-Meier method along with 95% exact confidence interval.
Other Outcome Measures
- Frequency of BCR-ABL fusion protein subtypes [Up to 12 months]
Descriptive statistics will be used to present the percentage of patients with a p190 versus p210 fusion protein at diagnosis, as measured in tumor tissues (peripheral blood, bone marrow aspirate) collected prior to treatment with venetoclax or dasatinib.
- Percent apoptosis (from baseline) following treatment with inhibitors of the various BH3 family member proteins [Up to 12 months]
Descriptive statistics will be used to present measurements made in tumor tissues (peripheral blood, bone marrow aspirate) collected prior to treatment with venetoclax or dasatinib.
- Frequency of gene mutations [Up to 12 months]
Descriptive statistics will be used to present measurements made in tumor tissues (peripheral blood, bone marrow aspirate) collected prior to treatment with venetoclax or dasatinib.
- Distribution of gene mutations [Up to 12 months]
Descriptive statistics will be used to present measurements made in tumor tissues (peripheral blood, bone marrow aspirate) collected prior to treatment with venetoclax or dasatinib.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects must have histologically confirmed diagnosis of B acute lymphoblastic leukemia harboring the t(9;22) translocation (Philadelphia chromosome positive acute lymphoblastic leukemia [Ph+ ALL]). All patients must have a bone marrow biopsy completed during the screening period. Patients with central nervous system (CNS) disease will be included
-
Newly diagnosed subjects must have received no prior treatment for their ALL with the exception of steroids (prednisone, dexamethasone), hydrea or IT methotrexate. Patients may receive pre-treatment with steroids during the screening phase prior to enrollment
-
Patients with relapsed disease may not have had prior treatment with dasatinib, however treatment with other tyrosine kinases is permitted
-
Age >= 18 years. All participants irrespective of their gender identity and members of all races and ethnic groups will be included
-
Eastern Cooperative Oncology Group (ECOG) status =< 2
-
Must be able to take oral medication
-
Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
-
Unless considered due to leukemic organ involvement
-
Alanine aminotransferase (ALT) < 2.5 x ULN
-
Unless considered due to leukemic involvement
-
Bilirubin < 1.5 x ULN
-
Unless considered due to leukemic organ involvement
-
Note: subjects with Gilbert's Syndrome may have a bilirubin > 1.5 x ULN per discussion between the investigator and AbbVie medical monitor
-
Subject must have adequate renal function as demonstrated by a calculated creatinine clearance >= 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft-Gault formula
-
Persons of childbearing potential must have a negative serum or urine pregnancy test (sensitivity < 25 IU human chorionic gonadotropin [HCG]/L) within 72 hours prior to the start of the study drug
-
Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped. Persons of childbearing potential and persons with a sexual partner of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy
-
Normal corrected QT (QTc) interval on screening electrocardiogram (EKG) (< 450 ms in men, < 470 ms in women)
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
For newly diagnosed subjects: who have received treatment with cytotoxic chemotherapy, radiotherapy or immunotherapy for their ALL, or prior dasatinib treatment. For relapsed subjects: prior dasatinib treatment (however treatment with other tyrosine kinase inhibitors [TKIs] is permitted)
-
Subjects who have received any investigational agents or subjects who are taking investigational or commercial agents or therapies with the intent to treat the subject's malignancy within seven days or three half-lives of enrollment (i.e. initiation of dasatinib)
-
Subjects with chronic myelogenous leukemia (CML) in myeloid blast crisis, Ph+ acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage
-
Subjects with clinically serious infections as determined by the provider requiring ongoing antibiotic therapy. This does not include antibiotic treatment for neutropenic fever
-
Patients with a pleural or pericardial effusion of any grade
-
Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or other agents used in the study
-
Subjects who have undergone stem cell transplant must be at least 100 days after transplant, and without active treatment for graft versus host disease (GVHD) other than topical medications
-
Subject has received the following within 7 days prior to the initiation of study treatment: Strong or moderate CYP3A inducers (such as rifampin, carbamazepine, phenytoin, and St. John's wort); warfarin or CYP3A inhibitors (such as fluconazole, ketoconazole and clarithromycin
-
Subjects with uncontrolled cardiac illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes), or pulmonary hypertension
-
Subjects with diagnosed congenital prolonged QT syndrome
-
Pregnant persons are excluded from this study because dasatinib is a pregnancy category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with dasatinib, breastfeeding should be discontinued if the mother is treated with dasatinib. These potential risks may also apply to venetoclax for which the pregnancy category and risks to the fetus are unknown
-
Participant is seropositive with human immunodeficiency virus (HIV) or has active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
-
For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
-
Individuals with a history of HCV infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Subjects with invasive malignancy over the previous year except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, completely resected papillary thyroid and follicular thyroid cancers, and localized prostate cancer treated with curative intent with surgery or radiation
-
Subjects with any gastrointestinal condition which would lead to inability to absorb an oral medication
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | OHSU Knight Cancer Institute | Portland | Oregon | United States | 97239 |
Sponsors and Collaborators
- OHSU Knight Cancer Institute
- AbbVie
- Oregon Health and Science University
Investigators
- Principal Investigator: Jessica T Leonard, OHSU Knight Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00022691
- NCI-2021-01791
- STUDY00022691